Chardan Capital Weighs In On Intellia Therapeutics’ FY2022 Earnings

Trending News 🌥️

Intellia Therapeutics ($NASDAQ:NTLA) is a leading biopharmaceutical company that uses cutting-edge gene editing technology to develop therapies for a range of diseases. The company’s stock has been on a tear lately, and Chardan Capital is weighing in on its FY2022 earnings. In a research report issued to clients and investors on Monday, February 8th, Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at Chardan Capital issued their FY2022 EPS estimates for shares of Intellia Therapeutics.

This is an exciting time for Intellia Therapeutics as it looks to continue its success in developing innovative gene editing therapies. With strong earnings estimates and a promising future, the company’s stock is one to watch in the coming year.

Earnings

In its earnings report for the fiscal year 2022 third quarter ended September 30, Intellia Therapeutics reported total revenue of $51.4 million and a net loss of $442.0 million. This represents a 55.3% increase in total revenue from the same period last year. Intellia Therapeutics’ total revenue has grown from $58.0 million to $51.4 million over the last three years. The company attributed the increase in revenue to higher collaboration and license agreement revenue, as well as higher grant and contract revenue.

Looking ahead, Intellia Therapeutics expects to continue to invest in research and development and expand its commercial operations. The company is also working on several clinical trials and expects to release data from these trials in the coming months.

Market Price

On Friday, shares of Intellia Therapeutics opened at $50.5 and closed at $48.8, representing a 0.4% decline from the previous day’s closing price of $49.0. This comes as Chardan Capital issued a report weighing in on the company’s earnings for the fiscal year 2022. The report also said that Intellia’s earnings are expected to be hurt by higher R&D expenses as the company continues to invest in its pipeline of gene editing therapies. Overall, Chardan Capital maintained a Neutral rating on Intellia stock with a price target of $50.

VI Analysis

VI’s analysis of INTELLIA THERAPEUTICS reveals 4 risk warnings in the company’s balance sheet, cashflow statement, non financial, and financial journal. Despite the company’s strong fundamentals, these risks make it a high risk investment. Register on VI to get more detailed information on these risks.

VI Peers

The company was founded in 2014 and is based in Cambridge, Massachusetts. Intellia has developed a platform that can be used to edit genes in a variety of cells and tissues. The company is also working on developing CRISPR-based treatments for diseases such as cancer and HIV. Intellia’s main competitors are CRISPR Therapeutics AG, Regeneron Pharmaceuticals Inc, and Editas Medicine Inc.

– CRISPR Therapeutics AG ($NASDAQ:CRSP)

Crispr Therapeutics AG is a biopharmaceutical company that focuses on the development of CRISPR/Cas9-based therapeutics for serious diseases. The company’s market cap as of 2022 is 4.28B and its ROE is -18.27%. Crispr Therapeutics AG was founded in 2013 and is headquartered in Zug, Switzerland.

– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)

Regeneron Pharmaceuticals Inc is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s products include EYLEA, Praluent, Dupixent, Libtayo, and Kevzara. As of 2021, the company had a market cap of $80.72 billion and a return on equity of 19.7%. Regeneron was founded in 1988 and is headquartered in Tarrytown, New York.

– Editas Medicine Inc ($NASDAQ:EDIT)

Editas Medicine Inc is a genome editing company based in Cambridge, Massachusetts. The company uses a technology called CRISPR to edit genes in order to treat genetic diseases. As of 2022, Editas Medicine Inc has a market cap of 886.02M and a Return on Equity of -23.75%. The company’s focus on genome editing makes it a leader in the field, and its market cap and ROE reflect this.

Summary

This cutting-edge technology has enormous potential in the treatment of genetic diseases, and Intellia is at the forefront of its development. The company is also well-funded, with a strong partnership with Novartis. This gives it the resources it needs to continue its research and development efforts.